Business Wire

Corporate Learning Technology Company Attensi Announces $26m Investment From Lugard Road Capital, DX Ventures, and Viking Venture for Global Expansion

8.4.2021 10:00:00 EEST | Business Wire | Press release

Share

Corporate Learning and Development (L&D) technology innovator Attensi is executing its plans for global expansion after raising $26m from New York-based Lugard Road Capital, DX Ventures, and existing share holder Viking Venture. The investment follows several years of rapid growth for the company, during which Attensi has recorded a 63% CAGR in annual recurring revenue and executed projects for a wide range of international blue-chip customers. The new funding will be used by Attensi to extend its presence in North America and Europe and to expand upon its leading product suite and technology platform in gamified simulations.

“Attensi solutions enable organizations to upskill their people faster, consistently, at scale, with results beyond the capabilities of traditional methods like e-learning, video, or classroom training. With gamified simulation training, we have combined the best of workplace psychology with our expertise in simulations and gamification to create a new category of training solutions. Our gamified simulations create significant real-world impact on companies’ core business metrics,” said Attensi Co-Founder and Co-CEO, Trond Aas. “This funding round enables our ambitious growth plans. With Lugard Road Capital we are bringing in a major US investor with experience of growing SaaS companies into global brands.”

With a client base that includes Daimler Mercedes Benz, Circle K, Equinor, BCG, and ASDA, Attensi uses a fusion of technology from the world of video gaming and insights from workplace psychology to train people via immersive, 3D simulations of their workplace and work processes. At the end of last year, the company announced plans to further develop its technology platform and enter new markets by the end of 2021. The fundraise from Lugard Road Capital, DX Ventures, and Viking Venture represents an acceleration of these plans.

Anne-Lise Waal, CTO and Co-CEO at Attensi said: “This is exciting news for everyone at Attensi. With the Attensi Technology Platform users across the globe can create high-end gamified solutions with our powerful no-code toolset. This investment will be instrumental in further expanding our cloud native SaaS platform and product suite. The Attensi Technology Platform will equip companies across all sectors to deliver on the challenge of continuous development and upskilling of their workforce. Our current plans for organizational expansion will see our staff count grow rapidly from the current level of 120 to well over 200.”

Doug Friedman, partner at Lugard Road Capital, said: “We could not be more excited to be investing in the Attensi team as they work to forever change and improve corporate learning and development through their Attensi solutions.”

Duncan McIntyre, Managing Director at DX Ventures, said: “Learning and development opportunities are becoming a decisive competitive factor to improve performance, attract and retain talent. We are thrilled to support Attensi to achieve its mission to make corporate training more effective and engaging.”

Eivind Bergsmyr, partner at Viking Venture, commented: “It’s been exciting to see the rapid growth and impressive development driven by the ability to bring in global top brands as customers during our time as investor in Attensi. This capital raise expands the investor universe with investors we know well from other Viking Venture portfolio companies and allows Attensi to continue its global expansion at increased pace.”

Established in 2012, Attensi has delivered gamified simulation training in more than 100 countries in 20 languages. Attensi solutions are used to simulate human interactions and work processes, including interpersonal ‘soft skills’, leadership training, use of IT-systems and any form of staff certification. Whether on mobile, desktop, or VR, Attensi’s gamified simulation approach enables organizations to upskill their people effectively, consistently, at scale, with all the data required to track impact on KPIs.

Attensi clients are corporate blue-chip companies in health care, pharmaceutical, financial services, professional services, retail, hospitality, manufacturing, shipping, offshore and transport, as well as public and third sectors. The company’s total revenue annual run-rate is currently $12m, and is headquartered in Oslo, Norway, with offices in London, UK, and Palo Alto, USA.

Pareto was engaged as Global Coordinator for the equity issue. GCA Altium is acting as the Global Financial Advisor to the company. Thommessen acted as the legal advisor in the transaction.

ENDS

Notes to editors:

About Attensi

Driven by the best of psychology, learning, and gaming, Attensi gamified simulation training engages your people with measurable impact on your KPIs. Whether on mobile, desktop, or VR, Attensi solutions empower people to learn new skills and behaviours in a fun, engaging way. The results enable organizations to excel in staff training, onboarding, and retention.

Attensi has delivered gamified simulation training in more than 100 countries, in 20 languages, and employs over 100 staff. Attensi is headquartered in Oslo, Norway, with offices in London, and Palo Alto, USA.

About Viking Venture

Viking Venture is the leading Nordic Software investor with more than NOK 3 billion under management. Since 2001, Viking Venture has invested in more than 50 Nordic companies with a particular focus on scaling Business-to-business (B2B) Software-as-a-Service (SaaS) companies. Viking Venture has been the lead investor of Attensi since 2018.

About Lugard Road Capital

Lugard Road Capital is a multi-billion-dollar global investment fund primarily focused on public and private companies in the Internet, software, consumer, and technology sectors.

About DX Ventures

DX Ventures is a venture capital fund backed by Delivery Hero. The fund’s mission is to support the next generation of founder-led companies that are disrupting some of the most rapidly changing industries around the world. The investment philosophy is centered on building long term partnerships with founders to provide support throughout the lifecycle and actively create value.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Steve Maybury | steve@opr.co.uk | +44 (0)7985774743
Aranda Rahbarkouhi | aranda@opr.co.uk | +44 (0)7807009347

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye